Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis

Journal of Nuclear Cardiology

Volumn 21, Issue 5, 2014, Pages 925-939

  Ahmadian, Azadeh ^a   Brogan, Ashley ^a   Berman, Jeffrey ^a   Sverdlov, Aaron L ^a   Mercier, Gustavo ^a   Mazzini, Michael ^a   Govender, Praveen ^a   Ruberg, Frederick L ^a   Miller, Edward J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

fluorodeoxyglucose (FDG); Metabolism: PET; PET CT imaging

Indexed keywords

FLUORODEOXYGLUCOSE; GLUCOSE; PREDNISONE; RUBIDIUM 82; TECHNETIUM 99M; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE ACTIVITY; ECHOCARDIOGRAPHY; FAINTNESS; FEMALE; FOLLOW UP; GLUCOSE TRANSPORT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE BIOPSY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL PERFUSION IMAGING; PET-CT SCANNER; RETROSPECTIVE STUDY; SARCOIDOSIS; SYMPTOM; TREATMENT RESPONSE; X RAY BONE DENSITOMETER; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; HEART DISEASES; IMAGE ENHANCEMENT; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

FEMALE; FLUORODEOXYGLUCOSE F18; HEART DISEASES; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MULTIMODAL IMAGING; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84907591099     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-014-9901-9     Document Type: Article

References (13)

1. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91. doi: 10.1016/j.hrthm.2012.02.010.
2. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11.
3. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.
4. Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28. doi: 10.1016/j.jcmg.2010.09.015.
5. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10. doi: 10.1007/s12350-009-9110-0.
6. Mc Ardle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J, et al. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron emission tomography? Circ Cardiovasc Imaging 2013;6:617-26. doi: 10.1161/CIRCIMAGING.112.000289.
7. Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2013. doi: 10.1007/s12350-013-9828-6.
8. Shah B, Srivastava N, Hirsch AE, Mercier G, Subramaniam RM. Intra-reader reliability of FDG PET volumetric tumor parameters: Effects of primary tumor size and segmentation methods. Ann Nucl Med 2012;26:707-14. doi: 10.1007/s12149-012-0630-3.
9. Tilkemeier PL, Cooke CD, Grossman GB, McCallister BD, Ward RP. Standardized reporting of radionuclide myocardial perfusion and function. J Nucl Cardiol 2009;16:650. doi: 10.1007/s12350-009-9095-8.
10. Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 2002;105:1144-5.
11. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501-11. doi: 10.1016/j.jcmg.2012.10.021.
12. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36. doi: 10.1016/j.jacc.2013.09.022.
13. Isiguzo MM, Brunken RR, Tchou PP, Xu M, Culver DA. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011;28:50-5.